Nathan J. Robison

Hematology | Oncology

550 S Beretania St Ste 201
Honolulu, HI 96813

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors.

Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors.

Journal: JCO oncology practice

Published: June 22, 2026

FOXR2-activated CNS neuroblastoma: Characterized by variable structural disruption of the FOXR2 regulatory region, recurrent copy number alterations, and elevated FOXR2 expression.

FOXR2-activated CNS neuroblastoma: Characterized by variable structural disruption of the FOXR2 regulatory region, recurrent copy number alterations, and elevated FOXR2 expression.

Journal: Neuro-oncology pediatrics

Published: April 14, 2026

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 13, 2026

Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.

Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.

Journal: Neuro-oncology

Published: January 19, 2026

Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma.

Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma.

Journal: Neuro-oncology

Published: January 19, 2026

Management of adverse events in patients with pediatric low-grade glioma treated with MAPK-directed therapies: Delphi consensus recommendations and unmet needs.

Management of adverse events in patients with pediatric low-grade glioma treated with MAPK-directed therapies: Delphi consensus recommendations and unmet needs.

Journal: Neuro-oncology practice

Published: August 14, 2025

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.

Journal: Neuro-oncology

Published: April 17, 2025

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 08, 2024

Effective re-induction regimen for children with recurrent medulloblastoma.

Effective re-induction regimen for children with recurrent medulloblastoma.

Journal: Neuro-oncology advances

Published: June 12, 2024

Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.

Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.

Journal: Neuro-oncology

Published: May 14, 2024

Lack of classical astroblastoma features in pediatric MN1::BEND2-fused brain tumors.

Lack of classical astroblastoma features in pediatric MN1::BEND2-fused brain tumors.

Journal: Brain pathology (Zurich, Switzerland)

Published: April 17, 2024

Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.

Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 26, 2024

Showing 1-12 of 47

Last Updated: 09/26/2026